发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape.
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-24 DOI: 10.1080/20468954.2025.2470102
Hai-Long Zhang, Zhaochen Lin, Ying Zhang
{"title":"Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape.","authors":"Hai-Long Zhang, Zhaochen Lin, Ying Zhang","doi":"10.1080/20468954.2025.2470102","DOIUrl":"https://doi.org/10.1080/20468954.2025.2470102","url":null,"abstract":"<p><p>PI3K and AKT signaling pathway has been linked to the pathophysiology of various diseases. This pathway has emerged as a crucial therapeutic strategy for cancer and other diseases. To better understand recent development of PI3K and AKT, a patent-based landscape study was performed. The results shows that both PI3K and AKT targets have shown prolific patent filings over the past 20 years. This study is the first to depict the therapeutic applications of both PI3K and AKT targets based on a patent big data analysis. Ten key therapeutic applications were identified, with over 77% of patents related to anti-cancer therapy for both PI3K and AKT targets. Additionally, our findings show that combination therapy is a distinguishing feature for drugs targeting both PI3K and AKT. The average time from patent application to drug approval for PI3K target drugs is 8.8 years. PI3K target drugs obtain market approval faster compared to AKT drugs. Approximately, 2 years of patent term extension could be obtained if the time from the patent application date to the drug approval date is less than 10 years.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs.
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-08 DOI: 10.1080/20468954.2025.2459582
Sarfaraz K Niazi
{"title":"Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs.","authors":"Sarfaraz K Niazi","doi":"10.1080/20468954.2025.2459582","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459582","url":null,"abstract":"<p><p>Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs due to the legal complexity and cost burden of resolving patent thickets accumulated by the originator companies. The United States Patent and Trademark Office (USPTO) proposed a change in the ruling in March 2024 to avoid double patenting if the patent to which it is tied in terminal disclaimer has any claims that have been invalidated as anticipated or obvious. This rule change aimed to promote innovation and competition by deterring strategies that leverage multiple patents for obvious variants to obstruct competitors. However, after receiving 349 comments on the proposed rule change, the USPTO withdrew its plan in December 2024 despite most comments favoring it. In a contrary move, the USPTO secured a court ruling that the terminal disclaimers do not apply to extended patent expiry due to the failure of the USPTO to prosecute a patent on a timely basis. The double patenting must end to enable more affordable generic and biosimilar drugs.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions.
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-05 DOI: 10.1080/20468954.2025.2459592
Absar Talat, Asad U Khan
{"title":"From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions.","authors":"Absar Talat, Asad U Khan","doi":"10.1080/20468954.2025.2459592","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459592","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging patents versus brain eating amoebae, Naegleria fowleri.
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-03 DOI: 10.1080/20468954.2025.2459584
Ruqaiyyah Siddiqui, David Lloyd, Naveed Ahmed Khan
{"title":"Emerging patents versus brain eating amoebae, <i>Naegleria fowleri</i>.","authors":"Ruqaiyyah Siddiqui, David Lloyd, Naveed Ahmed Khan","doi":"10.1080/20468954.2025.2459584","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459584","url":null,"abstract":"<p><p>Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae <i>Naegleria fowleri</i>. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreational water/or ablution/nasal irrigation with contaminated water. The management of PAM is hindered by the absence of effective treatment coupled with challenges in early diagnosis. This review explores emerging patents that could be utilized for the treatment, diagnosis of PAM, as well as water treatment. Recent patents from the past five years, along with research and innovations are reviewed and categorized into therapeutic agents, water treatment technologies, and diagnostic methods. It is hoped that collaboration and awareness between pharmaceutical companies, water industries, and academic institutions is essential for advancing effective strategies against this severe central nervous system pathogen.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights August-September 2023. 2023 年 8 月至 9 月的专利要点。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2024-03-18 DOI: 10.4155/ppa-2023-0039
Hermann Am Mucke
{"title":"Patent highlights August-September 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0039","DOIUrl":"https://doi.org/10.4155/ppa-2023-0039","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights June-July 2023. 2023 年 6 月至 7 月的专利亮点。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2024-03-18 DOI: 10.4155/ppa-2023-0035
Hermann Am Mucke
{"title":"Patent Highlights June-July 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0035","DOIUrl":"https://doi.org/10.4155/ppa-2023-0035","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights to the emerging potential of glucokinase activators as antidiabetic agent. 洞察葡萄糖激酶激活剂作为抗糖尿病药物的新兴潜力。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-09-11 DOI: 10.1080/20468954.2024.2389762
Anuradha Mehra, Shubham Kumar, Anu Mittal, Ruchi Kohli, Amit Mittal
{"title":"Insights to the emerging potential of glucokinase activators as antidiabetic agent.","authors":"Anuradha Mehra, Shubham Kumar, Anu Mittal, Ruchi Kohli, Amit Mittal","doi":"10.1080/20468954.2024.2389762","DOIUrl":"10.1080/20468954.2024.2389762","url":null,"abstract":"<p><p>The glucokinase enzyme (belongs to the hexokinase family) is present in liver cells and β-cells of the pancreas. Glucokinase acts as a catalyst in the conversion of glucose-6-phosphate from glucose which is rate-limiting step in glucose metabolism. Glucokinase becomes malfunctional or remains inactivated in diabetes. Glucokinase activators are compounds that bind at the allosteric site of the glucokinase enzyme and activate it. This article highlights the patent and recent research papers history with possible SAR from year 2014-2023. The data comprises the discussion of novel chemotypes (GKAs) that are being targeted for drug development and entered into clinical trials. GK activators have attracted massive interest since successful results have been reported from clinical trials data.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"53-71"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3D-printed immediate release solid dosage forms: a patent evaluation of US11622940B2. 三维打印速释固体制剂：US11622940B2 的专利评估。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-09-04 DOI: 10.1080/20468954.2024.2389774
Akshay Sharma, Ritu Rathi, Sanchay Sharma, Tanikan Sangnim, Kampanart Huanbutta, Inderbir Singh
{"title":"3D-printed immediate release solid dosage forms: a patent evaluation of US11622940B2.","authors":"Akshay Sharma, Ritu Rathi, Sanchay Sharma, Tanikan Sangnim, Kampanart Huanbutta, Inderbir Singh","doi":"10.1080/20468954.2024.2389774","DOIUrl":"10.1080/20468954.2024.2389774","url":null,"abstract":"<p><p>Three-dimensional (3D) printing is one of the most flexible technologies for preparing tablets, offering controlled drug release profiles. The current patent describes the preparation of immediate-release 3D-printed tablets of hydrochlorothiazide to improve disintegration and dissolution profile. The patent involves the preparation of drug-loaded filament via hot-melt extrusion and utilizing the same filaments for printing 3D-printed tablets using fused deposition modeling. The tablets were printed with different shapes and sizes by incorporating channels within the tablet spaces, termed as gaplets. The introduction of channels within the tablet design improves the disintegration and dissolution profile of the drug significantly. The morphological characteristic of 3D-printed tablets was studied by using scanning electron microscopy and revealed the presence of gaplets in the tablets.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"45-51"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights June-July 2023. 2023 年 6 月至 7 月的专利亮点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.4155/ppa-2023-0035
Hermann Am Mucke
{"title":"Patent Highlights June-July 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0035","DOIUrl":"10.4155/ppa-2023-0035","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"7-14"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights August-September 2023. 2023 年 8 月至 9 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI: 10.4155/ppa-2023-0039
Hermann Am Mucke
{"title":"Patent highlights August-September 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0039","DOIUrl":"https://doi.org/10.4155/ppa-2023-0039","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"15-22"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信